Chemoprevention of Pituitary Corticotroph Tumors
垂体促肾上腺皮质激素肿瘤的化学预防
基本信息
- 批准号:7065189
- 负责人:
- 金额:$ 7.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-11 至 2007-04-30
- 项目状态:已结题
- 来源:
- 关键词:Cushing&aposs syndromeadipocytesadrenocorticotropic hormoneapoptosisblood glucoseblood testschemopreventioncorticosteronecortisolcytokinedietary lipidgenetically modified animalshistopathologyhormone related neoplasm /cancerimidazolelaboratory mouseligandsliver functionnutrition aspect of cancerobesityperoxisome proliferator activated receptorpituitary neoplasmstriterpenesurinalysis
项目摘要
DESCRIPTION (provided by applicant): Cushing's disease, due to an ACTH-secreting pituitary tumor, causes illness due to excess steroid production; no suitable drug therapies are available, and surgical excision, is not always curative. We have demonstrated that ACTH-secreting pituitary tumors express abundant peroxisome proliferators activated receptor-gamma (PPAR-gamma). PPAR-gamma and the retinoid X receptor (RXR) form a permissive heterodimer, that can be activated by either PPAR-gamma and/ or RXR-specific ligands to regulate target gene transcription. Several natural occurring and synthetic PPAR-gamma ligands, including the thiazolidinedione (TZD), rosiglitazone; the non-TZD, GW7845; and the triterpenoid, cyano-3,12- dioxooleaneana-1,9(11)-dien-28-oyl]imidazole (CDDO-IM) bind PPAR-gamma, to regulate multiple actions. PPAR-gamma activation plays a critical role in adipogenesis, glucose metabolism, and placental function, and TZD's are widely used to treat diabetes. Treatment of human and mouse corticotroph pituitary tumor cells in vitro with PPAR-gamma ligands, inhibited tumor growth, and induced corticotroph tumor apoptosis. When athymic Nu/ Nu mice harboring subcutaneous xenografted corticotroph tumors, were treated with rosiglitazone, 4 of 5 treated mice did not develop tumors. Furthermore, plasma ACTH and corticosterone hormone levels were lower in rosiglitazone-treated animals. In addition, rosiglitazone, given to two patients with Cushing's disease, decreased 24 hour urinary cortisol levels by approximately 55% in one patient, and normalized cortisol levels in the second patient. Recently, we have demonstrated potent anti-proliferative, and pro-apoptotic actions of the PPAR-gamma ligand CDDO-IM in corticotroph tumor cells, using 1000-fold lower concentrations than rosiglitazone. This project will examine the chemopreventative actions of CDDO-IM in vivo in the Rb heterozygote knock-out mouse that develops spontaneous pituitary corticotroph tumor. We will also examine the effects of a high fat diet on pituitary corticotroph tumor development, and examine the role of chemopreventative anti-inflammatory treatment with CDDO-IM in the corticotroph tumor model. Our ultimate goal is to develop a rationale for clinical application of these PPAR-gamma ligands as a novel medical therapy in Cushing's disease.
描述(申请人提供):库兴氏病是由于一种分泌ACTH的脑下垂体瘤,由于类固醇的过度产生而引起的疾病;没有合适的药物治疗方法,手术切除并不总是治愈的。我们已经证明,分泌ACTH的垂体瘤表达丰富的过氧化物酶体增殖物激活受体-γ(PPAR-γ)。PPAR-γ和维甲酸X受体(RXR)形成一个允许的异源二聚体,可以被PPAR-γ和/或RXR特异性配体激活,以调节靶基因的转录。一些天然存在的和合成的PPAR-γ配体,包括噻唑烷二酮(TZD),罗格列酮,非TZD,GW7845,以及三萜类化合物,氰基-3,12-二氧杂环烷-1,9(11)-二烯-28-甲基咪唑(CDDO-IM)与PPAR-γ结合,以调节多种作用。PPAR-γ激活在脂肪生成、葡萄糖代谢和胎盘功能中起着关键作用,TZD被广泛用于治疗糖尿病。PPAR-γ配体体外处理人和小鼠促肾上腺皮质细胞瘤细胞,抑制肿瘤生长,并诱导促肾上腺皮质激素肿瘤细胞凋亡。用罗格列酮治疗皮下移植的裸鼠NU/NU小鼠时,5只小鼠中有4只未发生肿瘤。此外,罗格列酮治疗的动物血浆ACTH和皮质酮激素水平较低。此外,两名库欣病患者服用罗格列酮后,其中一名患者的24小时尿皮质醇水平降低了约55%,另一名患者的皮质醇水平恢复正常。最近,我们用比罗格列酮低1000倍的浓度证明了PPAR-γ配体CDDO-IM在促皮质激素肿瘤细胞中具有强大的抗增殖和促凋亡作用。本项目将检测CDDO-IM在Rb杂合子基因敲除小鼠中的化学预防作用,该小鼠患有自发性垂体促肾上腺皮质激素肿瘤。我们还将研究高脂饮食对垂体促肾上腺皮质细胞肿瘤发展的影响,并研究CDDO-IM在促肾上腺皮质细胞肿瘤模型中的化学预防性抗炎治疗的作用。我们的最终目标是为这些PPAR-伽马配体作为库欣病的一种新的药物疗法的临床应用提供理论基础。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Targeting pituitary tumors.
针对垂体肿瘤。
- DOI:10.1159/000110608
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Heaney,AnthonyP
- 通讯作者:Heaney,AnthonyP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTHONY P HEANEY其他文献
ANTHONY P HEANEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTHONY P HEANEY', 18)}}的其他基金
Development of a patient-derived tumoroid culture system to explore novel medical treatments for refractory prolactinomas
开发患者源性肿瘤培养系统,探索难治性泌乳素瘤的新疗法
- 批准号:
10643450 - 财政年份:2023
- 资助金额:
$ 7.62万 - 项目类别:
Identification of TR4 Modulators for Treatment of Cushing Disease.
用于治疗库欣病的 TR4 调节剂的鉴定。
- 批准号:
10199436 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10448514 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10653709 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10297675 - 财政年份:2021
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7904018 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
8137007 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7667840 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7502595 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7371529 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
相似海外基金
Structural and biochemical investigation of the Bloom�s complex, defective in Bloom�s Syndrome
布卢姆综合征缺陷的布卢姆复合体的结构和生化研究
- 批准号:
nhmrc : 1033592 - 财政年份:2012
- 资助金额:
$ 7.62万 - 项目类别:
NHMRC Project Grants
Immuno-pathophysiology of Lymphocytic Foci in Sjogren?s Syndrome
干燥综合征淋巴细胞病灶的免疫病理生理学
- 批准号:
8518291 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
An investigation of the role of brain amyloid in cognition, brain atrophy and Alzheimer s disease in Down s syndrome
脑淀粉样蛋白在唐氏综合症认知、脑萎缩和阿尔茨海默病中作用的研究
- 批准号:
G1002252/1 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
Research Grant
Immuno-pathophysiology of Lymphocytic Foci in Sjogren?s Syndrome
干燥综合征淋巴细胞病灶的免疫病理生理学
- 批准号:
8311959 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
Immuno-pathophysiology of Lymphocytic Foci in Sjogren?s Syndrome
干燥综合征淋巴细胞病灶的免疫病理生理学
- 批准号:
8321067 - 财政年份:2011
- 资助金额:
$ 7.62万 - 项目类别:
Immunotherapeutic analysis using newly established murine models for Sjogren' s syndrome
使用新建立的干燥综合征小鼠模型进行免疫治疗分析
- 批准号:
21249090 - 财政年份:2009
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Salivary glands reproduction and reacquisition of saliva secretion ability on the new Sjogren' s syndrome model mice.
新干燥综合征模型小鼠唾液腺的繁殖和唾液分泌能力的重新获得。
- 批准号:
21592530 - 财政年份:2009
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Research of γδ T cells in Sjogren, s syndrome model mouse
干燥综合征模型小鼠γδT细胞的研究
- 批准号:
19599009 - 财政年份:2007
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular analyses of UV^s syndrome and development of simple diagnostic methods for inherited photosensitive diseases
UV综合征的分子分析和遗传性光敏性疾病简单诊断方法的开发
- 批准号:
09670887 - 财政年份:1997
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)